ArticleBMC psychiatry2025
Efficacy and safety profile of vortioxetine as an add-on molecule in obsessive-compulsive disorder: a randomized double-blinded placebo-controlled superiority trial - a study protocol.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundObsessive-Compulsive Disorder (OCD) affects approximately 2-3% of the global population and is associated with significant functional impairment and reduced quality of life. Despite its widespread impact, pharmacological treatments approved by the U.S. Food and Drug Administration (FDA) for OCD remain limited. Vortioxetine is a multimodal antidepressant that obtained its FDA approval in December 2013 for Major Depressive Disorder (MDD) and has shown to have some potential benefits in terms of cognitive aspects and global manifestation of symptoms. The purpose of this study is to assess the effectiveness and safety of vortioxetine as adjunctive treatment in patients with a diagnosis of OCD. METHODS/
designA randomized, double-blind, placebo-controlled superiority trial, developed in accordance with CONSORT guidelines, will assess the efficacy and safety of vortioxetine in individuals diagnosed with OCD. A total of 114 participants who meet all eligibility criteria will be recruited and randomly allocated, using block randomization, into two equal treatment arms (n = 57 per group) following informed consent. The sample size provides 80% statistical power at a 5% significance level to detect a clinically meaningful difference of 5 units between the intervention and control groups. The experimental group will receive vortioxetine combined with escitalopram, and the control group will be administered a placebo with escitalopram. Demographic characteristics and disease profile at baseline will be collected using Case Report Forms (CRFs). The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and the Clinical Global Impressions (CGI) will be used to evaluate the outcomes at 4, 8, and 12 weeks. The Adverse Events and Side Events Checklist (ASEC) will document any adverse events reported by the patient throughout the trial participation. DISCUSSION: Vortioxetine's unique pharmacological profile may offer significant benefits to managing cognitive symptoms and improving the quality of life of OCD patients. This clinical trial aims to provide evidence on the clinical value and safety of vortioxetine in the management of OCD in order to advance the optimization of more effective and personalized treatment plans.
trial registrationThe trial was registered with the Clinical Trials Registry - India (CTRI) (registration ID: CTRI/2023/12/060748) on December 26, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.